Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy

Описание: Keypoints:
Datopotamab deruxtecan received Priority Review after promising data from the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 trials.
Patients with previously treated advanced EGFR-mutated non-small cell lung cancer may soon have a new treatment option.
Discussion on datopotamab deruxtecan adverse event profile.

At the American Society of Clinical Oncology Annual Meeting, Narjust Florez, MD, FASCO, Dana-Farber Cancer Institute, Boston, Massachusetts, weighed in on the potential FDA approval of datopotamab deruxtecan for previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC).
She discussed trial findings of the antibody-drug conjugate (ADC) with Coral Olazagasti, MD, University of Miami Health System, Miami, Florida. “We have to remember that it’s about patient selection for Dato,” Dr. Florez said.
Although the antibody-drug conjugate shows promising tumor responses, it also comes with significant toxicities, such as mouth ulcers and hair loss, that can affect a patient’s quality of life.
Earlier this year the FDA granted Priority Review for datopotamab deruxtecan treatment in adult patients with locally advanced or metastatic EGFR-mutated NSCLC based on data from the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 trials.
In these trials, datopotamab deruxtecan demonstrated a confirmed objective response rate of 42.7% as assessed by blinded independent central review and a median duration of response of 7 months.

Follow us on social media:
•⁠ ⁠X/Twitter:   / oncbrothers  
•⁠ ⁠Instagram:   / oncbrothers  
•⁠ Website: https://oncbrothers.com/
•⁠ Main Channel:    / @oncologybrothers